BY THE OPTIMIST DAILY EDITORIAL TEAM
For the first time ever, newborn babies have a malaria treatment made just for them. Swissmedic, Switzerland’s drug regulator, approved the world’s first malaria drug formulated specifically for infants under five kilograms. This is an enormous step forward in terms of protecting the youngest lives from one of the world’s deadliest diseases.
This new medication, developed by pharmaceutical company Novartis, addresses a long-standing gap in malaria care. While infants under two months are highly vulnerable, they’ve historically been given reduced doses of medications intended for older children, a workaround that increased their risk of side effects due to the way newborns metabolize drugs.
“Every one of those [babies] is a potential target for malaria infection,” said Dr. Lutz Hegemann, president of Novartis’ global health program. “We don’t want to leave any patient behind, no matter how small they are.”
A region in urgent need
The approval has particular significance for Africa, where malaria remains endemic and disproportionately deadly. According to the World Health Organization, malaria claimed approximately 597,000 lives in 2023, most of them children under five. Newborns, in particular, face heightened danger because malaria vaccines typically aren’t administered until around five months of age.
In 2023 alone, an estimated 36 million pregnancies occurred across 33 malaria-endemic countries in Africa. Roughly one in three expectant mothers contracted malaria, putting their babies at risk even before birth.
“There was a gap,” explained Dr. Quique Bassat, head of the Barcelona Institute of Global Health. “Now we have something which is perfectly suitable for that specific age group.”
A gentle but effective solution
The new treatment, called Coartem Baby, is a re-engineered version of Novartis’ existing pediatric antimalarial. Though similar in purpose, it contains a modified dose and ingredient ratio to minimize side effects in smaller, more vulnerable patients. Even the cherry flavour, which is dissolvable in breast milk, has been adjusted to make administration easier.
“These are small changes, but big steps,” said Bassat, who advised Novartis during clinical trials. The research was funded by the European Union and the Swedish International Development Cooperation Agency.
Late-stage clinical trial data confirmed the medication’s safety and effectiveness for infants under five kilograms, which typically are babies under two months old.
Fast-tracking approval in Africa
Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda are the eight African countries expected to swiftly approve and introduce the medicine. These nations are part of a collaborative initiative with Swissmedic to accelerate access to lifesaving drugs.
Novartis plans to begin distributing Coartem Baby in these countries by autumn, with more to follow. “We hope to roll the medicine out there this fall,” said Hegemann, emphasizing that the launch will be on a not-for-profit basis.
A hopeful future for malaria care
While the number of newborns diagnosed with malaria is relatively small compared to the broader disease burden, the impact of timely treatment at this stage is profound. “Those cases need to be treated, and therefore we need better drugs,” said Bassat.
With the approval of Coartem Baby, a critical health care gap has finally been addressed, offering hope to millions of families across Africa and marking a pivotal step in the global fight against malaria.
